Evidence map›Paper›PMID 19592089›Full record

ArticleBiomaterials2009

Simultaneous release of multiple molecules from poly(lactide-co-glycolide) nanoparticles assembled onto medical devices.

Catherine T Lo, Paul R Van Tassel, W Mark Saltzman

Abstract read
In one paragraph

Article in Biomaterials, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Designing drug-free biodegradable nanoparticles to modulate inflammatory monocytes and neutrophils for ameliorating inflammation.Journal of controlled release : official journal of the Controlled Release Society · 2019
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Catherine T LoDepartment of Biomedical Engineering, Yale University, Malone Engineering Center, Room 414, 55 Prospect Street, New Haven, CT 06511, USA.
Paul R Van Tassel
W Mark Saltzman

Funding

Microfluidic/controlled systems on brain microprobesR01NS045236 · NINDS · YALE UNIVERSITY · PI SALTZMAN, W MARK · 2003 to 2007
$1.3M
Pre-doctoral Training Program in Neuroengineering (RMI)R90DK071501 · NIDDK · YALE UNIVERSITY · PI SALTZMAN, W. MARK · 2004 to 2008
$59k
NIDDK NIH HHS R90 DK071501NINDS NIH HHS NS45236NINDS NIH HHS R01 NS045236
6 · The paper itself

Abstract

Cell and tissue responses to implanted biomaterials often limit their effectiveness and lifetime. This is particularly true for materials implanted into the brain. We present here a new approach for the modification of materials to enable release of multiple agents, which might be useful in modulating tissue responses, without changing the properties of the underlying material, in this case, a silicon probe. Poly(lactide-co-glycolide) nanoparticles (NPs) were assembled onto silicon probe surfaces by electrostatic interactions. Charged NPs were fabricated by altering the properties of the surfactant. NPs formed with poly(ethylene-alt-maleic anhydride) (PEMA) were strongly negatively charged; these NPs assembled onto probes best when suspended at nearly physiological conditions (surface density approximately 83,600+/-3000 particles/mm(2)). The percentage of surface area coverage by the NPs was estimated to be approximately 13% and was maintained over two weeks during constant exposure to PBS. Multiple fluorescent NP populations were attached to the same probe to allow visualization of simultaneous delivery of multiple agents by fluorescence microscopy. Release from NP coatings was reproducible and controllable. The distinct release profiles of each agent from the coatings were preserved upon attachment to the surfaces. The unique feature of this new system is that NPs encapsulating various molecules (i.e. drugs, proteins, or DNA) can be fabricated separately, in advance, and simply mixed prior to attachment. The versatility of this delivery system, therefore, makes it suitable for many applications.

Indexed as

Anti-Inflammatory AgentsCoated Materials, BiocompatibleDexamethasoneDrug CarriersFluorescent DyesNanoparticlesParticle SizePolyglactin 910SiliconStatic ElectricitySurface-Active AgentsSurface PropertiesAnti-Inflammatory AgentsCoated Materials, BiocompatibleDexamethasoneDrug CarriersFluorescent DyesPolyglactin 910SiliconSurface-Active Agents

Identifiers

PMID19592089
PMCPMC2742909

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.